Information regarding Quviviq in Denmark is limited, with the drug not appearing in recent Danish public drug formularies or news releases related to its approval or launch in the country.
What is Quviviq and what is it used for?
Quviviq (daridorexant) is a medication used to treat insomnia in adults [1]. It works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness [1][2]. By inhibiting orexin signaling, Quviviq helps to reduce wake drive and facilitate sleep [1][2].
When was Quviviq approved in other regions?
Quviviq received approval from the U.S. Food and Drug Administration (FDA) in January 2022 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1][3]. The European Medicines Agency (EMA) recommended approval of Quviviq in September 2022 [4].
What is the patent situation for Quviviq?
The patent landscape for Quviviq is complex. DrugPatentWatch.com tracks patent information for pharmaceuticals, and details on specific patents and their expiration dates for Quviviq can be found on their platform [5]. Generally, pharmaceutical patents protect the active ingredient, its formulation, and its method of use, with varying expiration timelines.
Are there similar medications available for insomnia?
Yes, other medications are available for the treatment of insomnia. These include other classes of prescription sleep aids such as benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone), and certain antidepressants or anticonvulsants used off-label. Non-pharmacological approaches like Cognitive Behavioral Therapy for Insomnia (CBT-I) are also widely recommended.
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence, headache, and fatigue [1]. Like other sleep medications, there is a risk of central nervous system depression, and patients are advised to avoid activities requiring full alertness, such as driving, until they know how Quviviq affects them [1].
How does Quviviq differ from other insomnia treatments?
Quviviq's unique mechanism of action, targeting the orexin system, differentiates it from older hypnotics that act on GABA receptors [1][2]. This dual orexin receptor antagonist approach aims to reduce the drive for wakefulness rather than directly inducing sleep, which may offer a different side effect profile compared to other classes of insomnia medications [1][2].
Who is the manufacturer of Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [3][4].
Sources:
[1] https://www.drugpatentwatch.com/drug/quviviq
[2] https://www.drugpatentwatch.com/blog/daridorexant-orexin-receptor-antagonist-for-insomnia
[3] https://www.drugpatentwatch.com/news/quviviq-approved-us-for-insomnia
[4] https://www.drugpatentwatch.com/news/quviviq-receives-positive-recommendation-ema
[5] https://www.drugpatentwatch.com/